Skip to content
OpenCapital
Get started

SIGA Technologies SIGA Cash & Equivalents

Cash & Equivalents at other companies

Emergent Biosolutions logo
Emergent BiosolutionsEBS
$161.5M+5.7%
Merck & Co. logo
Merck & Co.MRK
$5.4B-38.2%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$155.66M-43.4%
Septerna, Inc. logo
Septerna, Inc.SEPN
$71.61M-65.9%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$451.8M+323%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$198.2M-14.5%

Other financials

Income statement

See full
Revenue$6.2M-11.3%
Gross profit$3.3M-52.0%
Operating income-$5.3M-136%
Net income-$3.5M-746%
EPS (diluted)-$0.05-400%

Balance sheet

See full
Total debt$601.0K-50.6%
Total equity$151.6M-29.8%
Total assets$219.4M-11.2%

Cash flow

See full
Operating cash flow-$8.7M-223%
CapEx--100%
Free cash flow-$8.7M-223%

Valuation

See full
Market cap$261.08M-44.3%
Enterprise value$116.11M-59.6%
P/E10.3×+3.8×
P/S2.8×+0.2×

Profitability

See full
Gross margin65.4%-11.2pp
Operating margin52.4%-7.8pp
Net margin43.2%-6.1pp
FCF margin66.2%—

Returns & leverage

See full
Return on equity39.9%-18.5pp
Debt / equity0×0.0×
Current ratio3.2×-5.2×

Where this comes from

Reported directly by SIGA Technologies in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: SIGA Technologies’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about SIGA Technologies's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SIGA Technologies's cash & equivalents?
SIGA Technologies (SIGA) reported cash & equivalents of $145.56M in Q1 2026.
How has SIGA Technologies's cash & equivalents changed year-over-year?
SIGA Technologies's cash & equivalents decreased by 10.3% year-over-year, from $162.27M to $145.56M.
What is the long-term trend for SIGA Technologies's cash & equivalents?
Over 5 years (2020 to 2025), SIGA Technologies's cash & equivalents has grown at a 5.6% compound annual growth rate (CAGR), from $117.89M to $154.97M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.